Cumulative incidence of first recurrence after curative treatment of stage I–III colorectal cancer. Competing risk analyses of temporal and anatomic patterns

References

• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502. doi:10.1016/S0140-6736(13)61649-9.
   PubMed Web of Science ®Google Scholar
• Cancer in Norway 2020: cancer incidence, mortality, survival and prevalence in Norway. 2021. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf.
   Google Scholar
• Storli PE, Johnsen G, Juel IS, et al. Impact of increased resection rates and a liver parenchyma sparing strategy on long-term survival after surgery for colorectal liver metastases. A population-based study. Scand J Gastroenterol. 2019;54(7):890–898. doi:10.1080/00365521.2019.1641215.
   PubMed Web of Science ®Google Scholar
• Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in coorectal liver metastasis improves salvageability and survival. Ann Surg. 2016;263(1):146–152. doi:10.1097/SLA.0000000000001194.
   PubMed Web of Science ®Google Scholar
• van der Pool AEM, Damhuis RA, Ijzermans JNM, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14(1):56–61. doi:10.1111/j.1463-1318.2010.02539.x.
   PubMed Web of Science ®Google Scholar
• Elferink MA, de Jong KP, Klaase JM, et al. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis. 2015;30(2):205–212. doi:10.1007/s00384-014-2085-6.
   PubMed Web of Science ®Google Scholar
• Qaderi SM, Galjart B, Verhoef C, et al. Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. Int J Colorectal Dis. 2021;36(11):2399–2410. doi:10.1007/s00384-021-03914-w.
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Carr PR, Jansen L, et al. Time of metastasis and outcome in colorectal cancer. Ann Surg. 2019;269(3):494–502. doi:10.1097/SLA.0000000000002564.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448–454. doi:10.1016/j.canep.2014.04.004.
   PubMed Web of Science ®Google Scholar
• Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231. doi:10.1016/j.ejca.2008.10.037.
   PubMed Web of Science ®Google Scholar
• Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729–741. doi:10.1016/j.ctrv.2015.06.006.
   PubMed Web of Science ®Google Scholar
• Read TE, Mutch MG, Chang BW, et al. Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. J Am Coll Surg. 2002;195(1):33–40. doi:10.1016/s1072-7515(02)01224-3.
   PubMed Web of Science ®Google Scholar
• Elferink MA, Visser O, Wiggers T, et al. Prognostic factors for locoregional recurrences in colon cancer. Ann Surg Oncol. 2012;19(7):2203–2211. doi:10.1245/s10434-011-2183-4.
   PubMed Web of Science ®Google Scholar
• Wisselink DD, Klaver CEL, Hompes R, et al. Curative-intent surgery for isolated locoregional recurrence of colon cancer: review of the literature and institutional experience. Eur J Surg Oncol. 2020;46(9):1673–1682. doi:10.1016/j.ejso.2020.04.021.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observationa. Lancet. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X.
   PubMed Web of Science ®Google Scholar
• Allignol A, Schumacher M, Beyersmann J. A note on variance estimation of the Aalen-Johansen estimator of the cumulative incidence function in competing risks, with a view towards left-truncated data. Biom J. 2010;52(1):126–137. doi:10.1002/bimj.200900039.
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26(24):4027–4034. doi:10.1200/JCO.2007.12.9866.
   PubMed Web of Science ®Google Scholar
• Stensrud MJ, Hernan MA. Why test for proportional hazards? JAMA guide to statistics and methods. JAMA. 2020;323(14):1401–1402. doi:10.1001/jama.2020.1267.
   PubMed Web of Science ®Google Scholar
• Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in Colon cancer. Gastroenterology. 1994;106(4):899–906. doi:10.1016/0016-5085(94)90748-x.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351. doi:10.1056/NEJMoa032709.
   PubMed Web of Science ®Google Scholar
• Norwegian Rectal Cancer Registry, Norwegian Gastrointestinal Cancer Group (NGICG), annual report. 2009.
   Google Scholar
• Guren MG, Kørner H, Pfeffer F, et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncol. 2015;54(10):1714–1722. doi:10.3109/0284186X.2015.1034876.
   PubMed Web of Science ®Google Scholar
• WHO. Classification of tumours of the digestive system. 4th ed. Lyon: IARC Publications; 2010.
   Google Scholar
• Holmes AC, Riis AH, Erichsen R, et al. Descriptive characteristics of colon and rectal cancer recurrence in a danish population-based study. Acta Oncol. 2017;56(8):1111–1119. doi:10.1080/0284186X.2017.1304650.
   PubMed Web of Science ®Google Scholar
• Gately L, Jalali A, Semira C, et al. Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer. Acta Oncol. 2021;60(9):1106–1113. doi:10.1080/0284186X.2021.1943519.
   PubMed Web of Science ®Google Scholar
• Wibe A, Møller B, Norstein J, et al. A national strategic change in treatment policy for rectal cancer – implementation of total mesorectal excisison as routine treatment in Norway. A national audit. Dis Colon Rectum. 2002;45(7):857–866. doi:10.1007/s10350-004-6317-7.
   PubMed Web of Science ®Google Scholar
• Osterman E, Glimelius B. Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire swedish population. Dis Colon Rectum. 2018;61(9):1016–1025. doi:10.1097/DCR.0000000000001158.
   PubMed Web of Science ®Google Scholar
• Böckelman C, Engelmann BE, Kaprio T, et al. Risk of recurrence in patients with Colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54(1):5–16. doi:10.3109/0284186X.2014.975839.
   PubMed Web of Science ®Google Scholar
• Chandler I, Houlston RS. Interobserver agreement in grading of colorectal cancers – findings from a nationwide web-based survey of histopathologists. Histopathology. 2008;52(4):494–499. doi:10.1111/j.1365-2559.2008.02976.x.
   PubMed Web of Science ®Google Scholar
• Toh J, Chapuis PH, Bokey L, et al. Competing risks analysis of microsatellite instability as a prognostic factor in colorectal cancer. Br J Surg. 2017;104(9):1250–1259. doi:10.1002/bjs.10542.
   PubMed Web of Science ®Google Scholar
• Osterman E, Hammarstrøm K, Imam I, et al. Recurrence risk after radical colorectal cancer surgery – less than before, but how high is it? Cancers (Basel). 2020;12(11):3308. doi:10.3390/cancers12113308.
   PubMed Web of Science ®Google Scholar